Butterfield Joseph H
Division of Allergic Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Immunol Allergy Clin North Am. 2007 Aug;27(3):493-518. doi: 10.1016/j.iac.2007.06.003.
The hypereosinophilic syndromes continue to challenge our clinical acumen and skills. Prednisone, hydroxyurea, and interferon alpha 2b are three of the oldest agents that allow control of eosinophilia and its devastating clinical consequences. They still work. As our experience with them has grown, it has become evident that use of these agents in combination will control eosinophilia in most patients. Moreover, with time, the doses can frequently be reduced. Even with the advent of newer agents for treatment of hypereosinophilic syndromes, these three medications still afford an excellent, cost-effective avenue for disease management.
高嗜酸性粒细胞综合征持续考验着我们的临床洞察力和技能。泼尼松、羟基脲和干扰素α2b是最早用于控制嗜酸性粒细胞增多及其严重临床后果的三种药物。它们仍然有效。随着我们对它们的经验不断积累,很明显联合使用这些药物能控制大多数患者的嗜酸性粒细胞增多。此外,随着时间推移,剂量常常可以降低。即使有了治疗高嗜酸性粒细胞综合征的新型药物,这三种药物仍然为疾病管理提供了一条出色且性价比高的途径。